Omniscient to advance brain mapping with latest funding

Omniscient Neurotechnology on Monday announced the completion of an AUD 40 million ($29 million) Series B financing round to accelerate its research and product portfolio, and expand its science, engineering and sales teams globally. The company will also use the funds to expand market access to its Infinitome research platform as well as its recently FDA-cleared neurosurgical planning Quicktome platform.

According to Omniscient, its applications rely on medical imaging innovations and machine learning to model and analyse brain connectomics. The technology "transforms complex brain data into clear insight for doctors, psychologists, neuroscientists and brain technology innovators to better treat neurological disorders and mental illnesses," the company said.

"If you look at a brain scan today, many disorders such as depression are invisible – there's nothing physically there to see," explained chief medical officer Michael Sughrue, but "observing the brain's connections tells a very different story." He noted that "brain surgery is where we wanted to start, because neurosurgeons have an urgent need for brain mapping to guide surgical decisions."

Detailed look at connectomes

Quicktome is a digital brain mapping platform, recently cleared in the US, Canada and Australia, that allows neurosurgeons to visualise a patient's brain networks prior to performing surgery by analysing millions of data points derived from magnetic resonance imaging (MRI) scans. Omniscient said the majority of the analysis takes place in the cloud and can be accessed on a desktop computer.

Meanwhile, the company describes Infinitome is a next-generation neuro research platform that enables data and image analysis of the brain without the need for code. After conducting image and data processing of a patient's brain MRI, the platform uses machine learning to analyse how each brain region is wired and functions together. The technology allows "researchers to quickly identify patterns and regions of anomaly when investigating neurological and mental illnesses," Omniscient said.

Did you like this article?